VitaFlow LIBERTY 欧洲
VitaFlow Liberty™ 经导管主动脉瓣系统上市后临床随访研究
This is a prospective, single-arm, multi-center, observational, post-market clinical investigation to document the clinical safety and performance of MicroPort CardioFlow VitaFlow Liberty™ Transcatheter Aortic Valve System in the routine practice for the treatment of severe aortic valve stenosis. The primary endpoint is the composite rate of all-cause mortality and stroke with disability at 12 months.
Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Zhujun Cai, PhD
- 电话号码:86-021-38954600
- 邮箱:zjcai@microport.com
研究联系人备份
- 姓名:Yann Poezevara, PhD
- 电话号码:0033-146013409
- 邮箱:Yann.Poezevara@cf.microport.com
学习地点
-
-
-
Castel Volturno、意大利
- 招聘中
- Pineta Grande Hospital
-
接触:
- Alberto Morello
- 电话号码:+393397904191
- 邮箱:albertomorello83@gmail.com
-
Pisa、意大利
- 招聘中
- Ospedale Cisanello
-
接触:
- Dr.Marco De Carlo
- 电话号码:+39 050 971 9530
- 邮箱:urp@ao-pisa.toscana.it
-
Potenza、意大利
- 招聘中
- Azienda Ospedaliera Regionale -S.Carlo
-
接触:
- Eugenio Stabile
- 电话号码:+39 81 746 2228/53
- 邮箱:eugeniostabile@gmail.com
-
-
-
-
-
Galway、爱尔兰
- 招聘中
- Galway University Hospital
-
接触:
- Darren Mylotte, MD
-
-
-
-
-
Lucerne、瑞士
- 招聘中
- Luzerner Kantonsspital | Herzzentrum
-
接触:
- Dr.Stefan Toggweiler
- 电话号码:0412051111
- 邮箱:ifo@luks.ch
-
-
-
-
-
Carnaxide、葡萄牙
- 招聘中
- Hospital de Santa Cruz
-
接触:
- Rui Teles
- 电话号码:+351 21 043 1000
- 邮箱:rcteles@outlook.com
-
-
-
-
-
A Coruña、西班牙
- 招聘中
- Hospital Universitario de a Coruna
-
接触:
- Dr Pablo Pinon
- 电话号码:+34 981 17 80 00
- 邮箱:info@jjphospitalaria.com
-
Madrid、西班牙
- 招聘中
- Hospital Clínico San Carlos
-
接触:
- Dr.Luis Nombel
- 电话号码:91 330 30 00
- 邮箱:gerent.hcsc@salud.madrid.org
-
Valladolid、西班牙
- 招聘中
- Hospital clinico Universitario de Valladolid
-
接触:
- Dr. Filippo Pensotti
- 电话号码:+34 983 42 00 00
- 邮箱:ceim.asva@saludcastillayleon.esjalvarezgo
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with symptomatic, severe calcified aortic stenosis who are at high surgical risk.
描述
Inclusion Criteria:
- Subjects of age≥ 18 years
- Subjects with severe, symptomatic, calcific aortic stenosis who are considered at high risk for surgical aortic valve replacement (AVR).
- Subject can understand the purpose of the clinical investigation, has signed voluntarily the informed consent form and is agreeing to the scheduled follow up requirements.
Exclusion Criteria:
- Pre-existing mechanical heart valve in aortic position
- A known hypersensitivity or contraindication to all anticoagulation /antiplatelet regimens (or inability to be anticoagulated for the index procedure), to nickel or titanium, to nitinol, to dairy products, to polyethylene terephthalate (PET) or contrast media
- Ongoing sepsis, including active endocarditis
- Anatomically not suitable for the VitaFlow Liberty TAV system
- LVEF<20%
- Estimated life expectancy of less than 12 months
- Any medical, social or psychological condition that in the opinion of the Heart Team precludes the subject from receiving transcatheter aortic valve replacement
- Currently participating in another drug or device trial (excluding registries) for which the primary endpoint has not been assessed
- Inability to comply with the clinical investigation follow-up or other clinical investigation requirements
- Patients temporally unable to provide written informed consent (e. g. unconscious emergency patients)
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
单臂临床研究
|
Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System. Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Composite rate of all-cause mortality and stroke with disability
大体时间:12 months post procedure
|
Composite rate of all-cause mortality and stroke with disability |
12 months post procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety outcomes defined by VARC3
大体时间:30 days, 12 months, and 2-5 years post procedure
|
Rate of all-cause mortality, myocardial infarction, stroke, implanted related new and/or worsen conduction disturbances and arrhythmias, new permanent pacemaker implantation, procedure-related or valve-related hospitalization defined by VARC 3. |
30 days, 12 months, and 2-5 years post procedure
|
|
Safety outcomes defined by VARC3
大体时间:30 days and 12 months post procedure
|
Rate of type 2-4 bleeding, major vascular and access-related complications, acute kidney injury (stage 2-4) defined by VARC 3 |
30 days and 12 months post procedure
|
|
Safety outcomes defined by VARC3
大体时间:acute procedure (within 24 hours)
|
Rate of other acute procedural and technical valve related complications: conversion to surgery; unplanned use of mechanical circulatory support; implantation of multiple (>1) transcatheter valves during the index hospitalization; valve mal-position |
acute procedure (within 24 hours)
|
|
Device success
大体时间:30 days post implantation
|
Device success defined by VARC 3 |
30 days post implantation
|
|
Device early safety
大体时间:30 days post implantation
|
Device early safety defined by VARC 3 |
30 days post implantation
|
|
Bioprosthesis haemodynamic function
大体时间:Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
Bioprosthesis haemodynamic function (assessed by echocardiography) including effective orifice area (cm2). |
Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
|
Bioprosthesis haemodynamic function
大体时间:Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
Bioprosthesis haemodynamic function (assessed by echocardiography) including mean transvalvular gradient (mmHg). |
Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
|
Bioprosthesis haemodynamic function
大体时间:Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
Bioprosthesis haemodynamic function (assessed by echocardiography) including aortic regurgitation (paravalvular, central and total). |
Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
|
Bioprosthetic valve dysfunction
大体时间:12 months and 2-5 years post procedure
|
Moderate or severe haemodynamic valve deterioration defined by VARC3 |
12 months and 2-5 years post procedure
|
|
Bioprosthetic valve dysfunction
大体时间:12 months and 2-5 years post procedure
|
Bioprosthetic valve failure defined by VARC3 |
12 months and 2-5 years post procedure
|
|
Bioprosthetic valve dysfunction
大体时间:12 months and 2-5 years post procedure
|
Clinically significant valve thrombosis defined by VARC3 |
12 months and 2-5 years post procedure
|
|
NYHA Classification
大体时间:From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure
|
Changes in cardiac function at discharge, 30 days and 12 months and 2-5 years post implantation according to the NYHA Classification Scheme compared to baseline |
From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure
|
|
Rate of Alwide Plus Balloon Catheter pre-dilation success
大体时间:During procedure
|
Defined as successful access, delivery and dilation the aortic valve, and retrieval for the AlwideTM Plus balloon catheter |
During procedure
|
|
Alwide Plus Balloon Catheter related adverse-event
大体时间:Discharge
|
Discharge
|
|
|
Predictors for the permanent pacemaker implantation
大体时间:Baseline or intraprocedure
|
Including but not limited to pre-existing conduction disturbance, implant depth, LVOT calcium volume , post-dilatation |
Baseline or intraprocedure
|
合作者和调查者
调查人员
- 首席研究员:Darren Mylotte, MD、Galway University Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.